Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)
Status:
Completed
Trial end date:
2019-04-26
Target enrollment:
Participant gender:
Summary
The purpose of this study was to estimate the maximum tolerated dose and/or recommended dose
for expansion of LDK378 as a single agent, assess safety, tolerability and anti-tumor
activity and characterize single and multiple-dose pharmacokinetics when administered orally
to pediatric patients with ALK-activated tumors, with and without food.